reports
Lifecore Biomedical Hosts Virtual Investor Day
Lifecore Biomedical Hosts Virtual Investor Day CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it hosted a virtual investor day prior to market open during which Lifecore’s senior management team discussed the company’s business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore’s investor web page at: . ...
- Dave Nicoski
- Ross LaDuke
RRC RANGE RESOURCES CORPORATION
NWL NEWELL BRANDS INC
LNDC LANDEC CORP.
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
EOG EOG RESOURCES INC.
DAR DARLING INGREDIENTS INC.
COG CABOT OIL & GAS CORPORATION
AR ANTERO RESOURCES CORPORATION
AMP AMERIPRISE FINANCIAL INC.
PEN PENUMBRA INC.
GDEN GOLDEN ENTERTAINMENT
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
MBI MBIA INC.
SMPL SIMPLY GOOD FOODS CO
MCFT MASTERCRAFT BOAT HOLDINGS
NVST ENVISTA HOLDINGS
OVV OVINTIV INC
PL PLANET LABS PBC
ADTN ADTRAN HOLDINGS INC
DKNG DRAFTKINGS INC.
DEC DIVERSIFIED ENERGY COMPANY PLC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HBI HANESBRANDS INC.
ESE ESCO TECHNOLOGIES INC.
DGX QUEST DIAGNOSTICS INCORPORATED
DAR DARLING INGREDIENTS INC.
FLR FLUOR CORPORATION
HWBK HAWTHORN BANCSHARES
CENX CENTURY ALUMINUM COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
WEYS WEYCO GROUP INC.
PNRG PRIMEENERGY RESOURCES
TPB TURNING POINT BRANDS
SENEA SENECA FOODS CORP. CL A
AA ALCOA CORPORATION
LMB LIMBACH HOLDINGS
SRTS SENSUS HEALTHCARE
ATGE ADTALEM GLOBAL EDUCATION INC.
DESP DESPEGAR.COM CORP.
SMID SMITH MIDLAND
FGBI FIRST GUARANTY BANCSHARES
NVST ENVISTA HOLDINGS
AFRM AFFIRM HOLDINGS
SPNT SIRIUSPOINT LTD
LMND LEMONADE INC
PAY PAYMENTUS HLDGS INC
COIN COINBASE GLOBAL INC
RKLB ROCKET LAB USA INC
PPTA PERPETUA RESOURCES CORP
ROOT ROOT INC
LUNR INTUITIVE MACHINES INC
HIPO HIPPO HLDGS INC
BG BUNGE LIMITED
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
HOYFY HUHTAMAKI (VAN LEER) OYJ ADR 144A
UnitedHealth Group : 2 directors
A director at UnitedHealth Group gave away 8,000 shares at 0.000USD and the significance rating of the trade was 37/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Lifecore Biomedical to Present at Stephens Annual Investment Conferenc...
Lifecore Biomedical to Present at Stephens Annual Investment Conference CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the company’s president and chief executive officer, will be a featured speaker in a fireside chat at the upcoming Stephens Annual Investment Conference. The conference is being held November 19-21, 2024, in Nashville, Tennessee. Details regarding Lifecore’s participation are as follows: Stephens Annual ...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Trans...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third ...
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open ...
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024 CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore’s senior management team will discuss the company’s business and strategy for growt...
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and highlights. ...
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operat...
Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company’s Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company’s Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Life...
Oncocyte Announces Participation in the LD Micro Main Event XVII Confe...
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory () or request a meeting via the LD Micro Conference platform. Event: LD Micro Main Event...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezol...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed of positive data related to its proprietary gene expression test, DetermaIO™. The...
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Res...
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of 5-Head Isolator Filler; Increased Revenue Generating Potential to Up to $300 Million Annually -- -- Successfully Closed Financing Raising Approx. $24.3 Million, Providing Financial Runway for Current Liquidity Needs and Future Growth -- Conference Call Today at 8:30 a.m. ET CHASKA, Minn., Oct. 04...
Lifecore Biomedical Raises $24.3 Million in Private Placement of Commo...
Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock PIPE with New and Existing Investors Supports Working Capital and Operations CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $24.3 million private placement (“PIPE”) of 5,928,775 shares of its common stock at a price of $4.10 per share. The investing group includes new and existing shareholders, and the company expects to use the proceeds for working capital...
Lifecore Biomedical to Report Financial Results for First Quarter of F...
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024 CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter...
Oncocyte Signs Leading Transplant Centers in US and Germany
Oncocyte Signs Leading Transplant Centers in US and Germany GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has submitted a Q-Sub to the FDA IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both have entered into agreements with the...
Oncocyte Corporation Announces $10.2 Million Private Placement of Secu...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. Th...
Lifecore Biomedical Selected by Lindy Biosciences to Support Process D...
Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences’ Preferred CDMO Offers Lifecore Key Access Point into Manufacture and Fill/Finish of Next-Generation Biotherapeutic Formulations with Potential to Deliver Significant Benefits to Patients Worldwide CHASKA, Minn., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and m...
Lifecore Biomedical to Participate at Upcoming Industry Conferences an...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at four upcoming industry events. Details of the company’s activities at these events are as follows: Medical Aesthetic Injectable Summit 2024Conference Date/Location: October 4-5, 2024, in Marbella, SpainDetails: Darren Hieber, Lifecore’s senior vice president of corporate develo...
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolato...
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for Fill/Finish of Latest Sterile Injectable Pharmaceutical and Biopharmaceutical Products Current Capacity More than Doubles with New Filler CHASKA, Minn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufactur...
Adtalem Global Education Inc: 2 directors
Two Directors at Adtalem Global Education Inc sold/sold after exercising options 83,433 shares at between 70.543USD and 72.786USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.